SciBX: Science-Business eXchange Contents: February 7 2013, Volume 6 / Issue 5

TABLE OF CONTENTS February 7 2013, Volume 6 / Issue 5 Analysis Cover Story Targets and Mechanisms Tools The Distillery: Therapeutics Cancer Endocrine/metabolic disease Hematology Hepatic disease Infectious disease Neurology Various The Distillery: Techniques Assays and screens Disease models Drug platforms Imaging Advertisement BioPharma Dealmakers A supplement to Nature Biotechnology and Nature Reviews Drug Discovery The June 2012 issue of BioPharma Dealmakers showcases companies with partnering opportunities within the academic and vaccine fields in the U.S and abroad. This week, find out about how you can collaborate with Merck. New Partnering Opportunities in Alzheimer's Disease! A comprehensive interactive dashboard from Relay Technology Management.  Click here for more information on Alzheimer's partnering opportunities.   SciBX: Science-Business eXchange Recommend SciBX to your library today SciBx is a weekly publication that identifies and analyzes the most important translational research articles from over 40 journals. Find out which papers have real scientific and commercial potential, and why. Subscribe to SciBX and you won't miss the next big thing. For more information visit: www.nature.com/scibx.   Trade Secrets A Nature Network blog by BIOENTREPRENEUR Brought to you by Nature Biotechnology Access the insights, advice and commentary from scientists and entrepreneurs building biotech sectors around the world. Join the global dialogue on life science entrepreneurship: http://blogs.nature.com/trade_secrets   Analysis Cover Story Top 2012 gets a new deal Kai-Jye Lou doi:10.1038/scibx.2013.105 SciBX's second annual global analysis of public-private partnerships and early stage venture financing activity reveals that government institutions are taking a significant role in forming and funding PPPs, and California-based companies are leading the way in PPP activity. Full Text | PDF Targets and Mechanisms Top Zelboraf dosing rework Tim Fulmer doi:10.1038/scibx.2013.106 NIBR and UCSF researchers have shown that altering the dosing regimen of Zelboraf can prevent the development of drug resistance in mouse models of melanoma. The team will now test an intermittent Zelboraf dosing regimen in patients with melanoma. Full Text | PDF Tools Top Rejuvenating T cells Tracey Baas doi:10.1038/scibx.2013.107 Two Japanese teams have used iPS cells to regenerate antigen-specific T cells in patients whose immune systems have been depleted. Megakaryon is developing the technology of one group to produce iPS cell–derived human T cells. Full Text | PDF Sequencing single B cells Lauren Martz doi:10.1038/scibx.2013.108 University of Texas researchers have developed a high throughput method for sequencing individual B cell immunoglobulin receptors that keeps the link between their paired heavy and light variable chains intact. The next step is modifications to increase throughput and accuracy. Full Text | PDF Distillery: Therapeutics Cancer Top IL-20; IL-20 receptor-α (IL20R1; IL20RA); cyclin-dependent kinase inhibitor 1A (p21, Cip1) (CDKN1A; CIP1) doi:10.1038/scibx.2013.109 Patient sample and cell culture studies suggest inhibiting IL-20 could help treat muscle-invasive bladder cancer. Full Text | PDF Baculoviral IAP repeat-containing 2 (BIRC2; cIAP1); x-linked inhibitor of apoptosis (XIAP) doi:10.1038/scibx.2013.110 Mouse and cell culture studies identified bicyclic octahydropyrrolo[1,2-α]pyrazine–based inhibitors of cIAP1 that could help treat cancer. Full Text | PDF Tankyrase TRF1-interacting ankyrin-related ADP-ribose polymerase (TNKS) doi:10.1038/scibx.2013.111 An SAR study identified TNKS inhibitors that could help treat cancer. Full Text | PDF Mixed lineage kinase 4 (KIAA1804; MLK4); K-Ras doi:10.1038/scibx.2013.112 An in vitro and mouse study suggests inhibiting MLK4 could help treat a subset of colorectal cancers with mutant K-Ras. Full Text | PDF B cell lymphoma 2 (BCL-2; BCL2) doi:10.1038/scibx.2013.113 Mouse and cell culture studies suggest BCL-2 inhibitors could be useful for selectively killing leukemia stem cells. Full Text | PDF Endocrine/metabolic disease Top Growth hormone–releasing hormone receptor (GHRHR); GHRH doi:10.1038/scibx.2013.114 In vitro and mouse studies suggest pancreatic islet cells pretreated with GHRHR agonists and transplanted into the adrenal gland could help treat diabetes. Full Text | PDF Hematology Top Solute carrier family 2 facilitated glucose transporter member 1 (SLC2A1; GLUT1) doi:10.1038/scibx.2013.115 In vitro and mouse studies suggest inhibiting GLUT1 could help prevent weight loss associated with myeloproliferative disorder. Full Text | PDF Hepatic disease Top Fibroblast growth factor 7 (FGF7) doi:10.1038/scibx.2013.116 Mouse studies suggest FGF7 could help activate liver progenitor cells (LPCs) to treat liver diseases. Full Text | PDF Infectious disease Top Not applicable doi:10.1038/scibx.2013.117 In vitro studies identified a short, membrane-disrupting peptide that could help treat bacterial infections. Full Text | PDF Solute carrier family 10 sodium/bile acid cotransporter family member 1 (SLC10A1) doi:10.1038/scibx.2013.118 In vitro and cell culture studies suggest antagonizing SLC10A1 on host cells could help prevent HBV and HDV infection. Full Text | PDF HCV NS3/4A protease complex doi:10.1038/scibx.2013.119 In vitro studies identified a macrocyclic acyl sulfonamide–based inhibitor of HCV NS3/4A protease that could help treat drug-resistant HCV infection. Full Text | PDF Neurology Top Macrophage colony-stimulating factor 1 (CSF1; M-CSF); IL-34; colony-stimulating factor 1 receptor (CSF1R; C-FMS; CD115) doi:10.1038/scibx.2013.120 Mouse and cell culture studies suggest increasing CSF1R signaling could protect neurons to help treat brain injury and neurodegenerative diseases. Full Text | PDF Various Top Not applicable doi:10.1038/scibx.2013.121 Mouse studies suggest enteric microbiota from males could help protect females from type 1 diabetes. Full Text | PDF Distillery: Techniques Assays and screens Top High throughput sequencing strategy for pairs of immunoglobulin heavy (VH) and light (VL) variable regions doi:10.1038/scibx.2013.122 A method to sequence paired VH and VL regions could help improve the design of vaccines, therapeutics and diagnostics. Full Text | PDF Localized intracellular proteome analysis using a spatially restricted enzymatic tag doi:10.1038/scibx.2013.123 Localized intracellular proteome analysis could be used as a discovery tool to map the protein components of organelles in diseased cells. Full Text | PDF Disease models Top Humanized mouse model for graft-versus-host disease (GvHD) prevention by Treg cells doi:10.1038/scibx.2013.124 A humanized mouse model for GvHD could be useful for testing the therapeutic potential of cultured human Treg cells. Full Text | PDF Drug platforms Top Clustered, regularly interspaced short palindromic repeats (CRISPR) RNA editing system to modify genomic DNA doi:10.1038/scibx.2013.125 Four independent teams developed CRISPR-derived genome editing systems that could be used to modify genomic DNA in diverse biological systems. Full Text | PDF Pluripotent cell–specific inhibitors (PluriSIns) to reduce the tumorigenic risk of stem cell–based therapies doi:10.1038/scibx.2013.126 PluriSIns that are selectively toxic to human pluripotent stem cells could reduce the tumorigenic risk of stem cell–based therapies. Full Text | PDF Imaging Top Endomicroscopy capsule for diagnosing upper GI tract disease doi:10.1038/scibx.2013.127 A disposable, tethered endomicroscopy capsule could be used to provide 3D microscopic images of the upper GI tract to help diagnose disease. Full Text | PDF You have been sent this Table of Contents Alert because you have opted in to receive it. You can change or discontinue your e-mail alerts at any time, by modifying your preferences on your nature.com account at: www.nature.com/myaccount (You will need to log in to be recognised as a nature.com registrant) For further technical assistance, please contact our registration department For print subscription enquiries, please contact our subscription department For other enquiries, please contact our customer feedback department Nature Publishing Group | 75 Varick Street, 9th Floor | New York | NY 10013-1917 | USA Nature Publishing Group's worldwide offices: London - Paris - Munich - New Delhi - Tokyo - Melbourne San Diego - San Francisco - Washington - New York - Boston Macmillan Publishers Limited is a company incorporated in England and Wales under company number 785998 and whose registered office is located at Brunel Road, Houndmills, Basingstoke, Hampshire RG21 6XS. © 2013 Nature Publishing Group, a division of Macmillan Publishers Limited. All Rights Reserved.